Cargando…

Levels of Soluble Receptor for Advanced Glycation End Products in Bronchoalveolar Lavage Fluid in Patients with Various Inflammatory Lung Diseases

Receptor for advanced glycation end products (RAGE) is a multiligand receptor of S100/calgranulins, high-mobility group box 1, and others, and it is associated with the pathogenesis of various inflammatory and circulatory diseases. The soluble form of RAGE (sRAGE) is a decoy receptor and competitive...

Descripción completa

Detalles Bibliográficos
Autores principales: Kamo, Tetsuro, Tasaka, Sadatomo, Tokuda, Yuriko, Suzuki, Shoji, Asakura, Takanori, Yagi, Kazuma, Namkoong, Ho, Ishii, Makoto, Hasegawa, Naoki, Betsuyaku, Tomoko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Libertas Academica 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4852761/
https://www.ncbi.nlm.nih.gov/pubmed/27147899
http://dx.doi.org/10.4137/CCRPM.S23326
_version_ 1782429986756493312
author Kamo, Tetsuro
Tasaka, Sadatomo
Tokuda, Yuriko
Suzuki, Shoji
Asakura, Takanori
Yagi, Kazuma
Namkoong, Ho
Ishii, Makoto
Hasegawa, Naoki
Betsuyaku, Tomoko
author_facet Kamo, Tetsuro
Tasaka, Sadatomo
Tokuda, Yuriko
Suzuki, Shoji
Asakura, Takanori
Yagi, Kazuma
Namkoong, Ho
Ishii, Makoto
Hasegawa, Naoki
Betsuyaku, Tomoko
author_sort Kamo, Tetsuro
collection PubMed
description Receptor for advanced glycation end products (RAGE) is a multiligand receptor of S100/calgranulins, high-mobility group box 1, and others, and it is associated with the pathogenesis of various inflammatory and circulatory diseases. The soluble form of RAGE (sRAGE) is a decoy receptor and competitively inhibits membrane-bound RAGE activation. In this study, we measured sRAGE levels in bronchoalveolar lavage fluid (BALF) of 78 patients, including 41 with interstitial pneumonia, 11 with sarcoidosis, 9 with respiratory infection, 7 with ARDS, 5 with lung cancer, and 5 with vasculitis. Among them, sRAGE was detectable in BALF of 73 patients (94%). In patients with ARDS and vasculitis, the sRAGE levels were significantly higher than in the control subjects and those with interstitial pneumonia. The sRAGE levels were positively correlated with total cell counts in BALF and serum levels of surfactant protein-D, lactate dehydrogenase, and C-reactive protein. There was an inverse correlation between PaO(2)/FIO(2) ratio and sRAGE levels. These results indicate that sRAGE in BALF might be considered as a biomarker of lung inflammatory disorders, especially ARDS and vasculitis.
format Online
Article
Text
id pubmed-4852761
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Libertas Academica
record_format MEDLINE/PubMed
spelling pubmed-48527612016-05-04 Levels of Soluble Receptor for Advanced Glycation End Products in Bronchoalveolar Lavage Fluid in Patients with Various Inflammatory Lung Diseases Kamo, Tetsuro Tasaka, Sadatomo Tokuda, Yuriko Suzuki, Shoji Asakura, Takanori Yagi, Kazuma Namkoong, Ho Ishii, Makoto Hasegawa, Naoki Betsuyaku, Tomoko Clin Med Insights Circ Respir Pulm Med Original Research Receptor for advanced glycation end products (RAGE) is a multiligand receptor of S100/calgranulins, high-mobility group box 1, and others, and it is associated with the pathogenesis of various inflammatory and circulatory diseases. The soluble form of RAGE (sRAGE) is a decoy receptor and competitively inhibits membrane-bound RAGE activation. In this study, we measured sRAGE levels in bronchoalveolar lavage fluid (BALF) of 78 patients, including 41 with interstitial pneumonia, 11 with sarcoidosis, 9 with respiratory infection, 7 with ARDS, 5 with lung cancer, and 5 with vasculitis. Among them, sRAGE was detectable in BALF of 73 patients (94%). In patients with ARDS and vasculitis, the sRAGE levels were significantly higher than in the control subjects and those with interstitial pneumonia. The sRAGE levels were positively correlated with total cell counts in BALF and serum levels of surfactant protein-D, lactate dehydrogenase, and C-reactive protein. There was an inverse correlation between PaO(2)/FIO(2) ratio and sRAGE levels. These results indicate that sRAGE in BALF might be considered as a biomarker of lung inflammatory disorders, especially ARDS and vasculitis. Libertas Academica 2016-04-28 /pmc/articles/PMC4852761/ /pubmed/27147899 http://dx.doi.org/10.4137/CCRPM.S23326 Text en © 2015 the author(s), publisher and licensee Libertas Academica Ltd. This is an open-access article distributed under the terms of the Creative Commons CC-BY-NC 3.0 License.
spellingShingle Original Research
Kamo, Tetsuro
Tasaka, Sadatomo
Tokuda, Yuriko
Suzuki, Shoji
Asakura, Takanori
Yagi, Kazuma
Namkoong, Ho
Ishii, Makoto
Hasegawa, Naoki
Betsuyaku, Tomoko
Levels of Soluble Receptor for Advanced Glycation End Products in Bronchoalveolar Lavage Fluid in Patients with Various Inflammatory Lung Diseases
title Levels of Soluble Receptor for Advanced Glycation End Products in Bronchoalveolar Lavage Fluid in Patients with Various Inflammatory Lung Diseases
title_full Levels of Soluble Receptor for Advanced Glycation End Products in Bronchoalveolar Lavage Fluid in Patients with Various Inflammatory Lung Diseases
title_fullStr Levels of Soluble Receptor for Advanced Glycation End Products in Bronchoalveolar Lavage Fluid in Patients with Various Inflammatory Lung Diseases
title_full_unstemmed Levels of Soluble Receptor for Advanced Glycation End Products in Bronchoalveolar Lavage Fluid in Patients with Various Inflammatory Lung Diseases
title_short Levels of Soluble Receptor for Advanced Glycation End Products in Bronchoalveolar Lavage Fluid in Patients with Various Inflammatory Lung Diseases
title_sort levels of soluble receptor for advanced glycation end products in bronchoalveolar lavage fluid in patients with various inflammatory lung diseases
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4852761/
https://www.ncbi.nlm.nih.gov/pubmed/27147899
http://dx.doi.org/10.4137/CCRPM.S23326
work_keys_str_mv AT kamotetsuro levelsofsolublereceptorforadvancedglycationendproductsinbronchoalveolarlavagefluidinpatientswithvariousinflammatorylungdiseases
AT tasakasadatomo levelsofsolublereceptorforadvancedglycationendproductsinbronchoalveolarlavagefluidinpatientswithvariousinflammatorylungdiseases
AT tokudayuriko levelsofsolublereceptorforadvancedglycationendproductsinbronchoalveolarlavagefluidinpatientswithvariousinflammatorylungdiseases
AT suzukishoji levelsofsolublereceptorforadvancedglycationendproductsinbronchoalveolarlavagefluidinpatientswithvariousinflammatorylungdiseases
AT asakuratakanori levelsofsolublereceptorforadvancedglycationendproductsinbronchoalveolarlavagefluidinpatientswithvariousinflammatorylungdiseases
AT yagikazuma levelsofsolublereceptorforadvancedglycationendproductsinbronchoalveolarlavagefluidinpatientswithvariousinflammatorylungdiseases
AT namkoongho levelsofsolublereceptorforadvancedglycationendproductsinbronchoalveolarlavagefluidinpatientswithvariousinflammatorylungdiseases
AT ishiimakoto levelsofsolublereceptorforadvancedglycationendproductsinbronchoalveolarlavagefluidinpatientswithvariousinflammatorylungdiseases
AT hasegawanaoki levelsofsolublereceptorforadvancedglycationendproductsinbronchoalveolarlavagefluidinpatientswithvariousinflammatorylungdiseases
AT betsuyakutomoko levelsofsolublereceptorforadvancedglycationendproductsinbronchoalveolarlavagefluidinpatientswithvariousinflammatorylungdiseases